Abstract
The aim of the current study was to analyze the susceptibility of gram-positive and -negative clinical isolates to a novel des-F(6)-quinolone (nemonoxacin) and other selected antimicrobial agents. Minimal inhibitory concentrations (MICs) were determined by the agar plate dilution method according to NCCLs. Nemonoxacin exhibited greater antimicrobial activity than other quinolones, such as ciprofloxacin, levofloxacin, and moxifloxacin, and other antimicrobials when tested against selected gram-positive organisms. This non-fluorinated quinolone was especially active against streptococci and staphylococci, including multi-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA). Compared with ciprofloxacin, levofloxacin, and moxifloxacin, and other antimicrobials, nemonoxacin was not highly active against all tested gram-negative clinical isolates, with an MIC90 of 8-32 μg/mL. Nemonoxacin has powerful antibacterial activity against gram-positive strains and has value in treating quinolone-resistant clinical isolates of MSSA, MRSA, and S. pneumoniae infections. Nemonoxacin should not be the first choice to treat gram-negative clinical isolate infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
